The role of allergen immunotherapy in the management of allergic rhinitis

American Journal of Rhinology and Allergy

Volumn 30, Issue 1, 2016, Pages 48-53

  Cox, Linda ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; CORTICOSTEROID;

ALLERGIC RHINITIS; ANAPHYLAXIS; ARTICLE; ASTHMA; COST CONTROL; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL MANAGEMENT; ERYTHEMA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY; IMMUNOTHERAPY; INJECTION SITE SWELLING; MAINTENANCE THERAPY; PREVALENCE; PRURITUS; QUALITY OF LIFE; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TREATMENT DURATION; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DESENSITIZATION; DRUG THERAPY; ECONOMICS; IMMUNOLOGY; PHARMACOECONOMICS; PROCEDURES; RHINITIS, ALLERGIC; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; UNITED STATES;

ADMINISTRATION, SUBLINGUAL; COST-BENEFIT ANALYSIS; DESENSITIZATION, IMMUNOLOGIC; DRUG THERAPY; ECONOMICS, PHARMACEUTICAL; HUMANS; INJECTIONS, SUBCUTANEOUS; QUALITY OF LIFE; RHINITIS, ALLERGIC; UNITED STATES;

EID: 84959519112     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2016.30.4253     Document Type: Article

References (86)

1. Burgess JA, Walters EH, Byrnes GB, et al. Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: A longitudinal study. J Allergy Clin Immunol 120:863-869, 2007.
2. Baena-Cagnani CE, Canonica GW, Zaky Helal M, et al. The international survey on the management of allergic rhinitis by physicians and patients (ISMAR). World Allergy Organ J 8:10, 2015.
3. Kreiner-Moller E, Chawes BL, Caye-Thomasen P, Bonnelykke K, Bisgaard H. Allergic rhinitis is associated with otitis media with effusion: a birth cohort study. Clin Exp Allergy 42:1615-1620, 2012.
4. Ozdoganoglu T, and Songu M. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis 6:11-23, 2012.
5. Valovirta E (Ed). EFA Book on Respiratory Allergies. Brussels, Belgium: European Federation of Allergy and Airways Diseases Patients Associations, 2011.
6. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1-S84, 2008.
7. CDC Fast Facts A-Z, Vital Health Statistics, 2003. Available online at http://www.aafa.org/display.cfm?id=9&sub=30; accessed May 22, 2011.
8. Bauchau V, and Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 24:758-764, 2004.
9. Bunyavanich S, Soto-Quiros ME, Avila L, et al. Risk factors for allergic rhinitis in Costa Rican children with asthma. Allergy 65:256-263, 2010.
10. Maurer M, and Zuberbier T. Undertreatment of rhinitis symptoms in Europe: Findings from a cross-sectional questionnaire survey. Allergy 62:1057-1063, 2007.
11. Sazonov V, Ambegaonkar BM, Bolge SC, et al. Frequency of diagnosis and treatment of allergic rhinitis among adults with asthma in Germany, France, and the UK: National Health and Wellness Survey. Curr Med Res Opin 25:1721-1726, 2009.
12. Nolte H, Nepper-Christensen S, and Backer V. Unawareness and undertreatment of asthma and allergic rhinitis in a general population. Respir Med 100:354-362, 2006.
13. Soni A. Medical Expenditure Panel Survey. Statistical Brief no. 204: Allergic Rhinitis: Trends in Use and Expenditures, 2000 and 2005. Bethesda, MD: Agency for Healthcare Research and Quality, 2008. Available online at meps.ahrq.gov/mepsweb/data-files/publications/st204/stat204.pdf; accessed May 26, 2015.
14. Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc 31:375-380, 2010.
15. Schultz AB, Chen CY, and Edington DW. The cost and impact of health conditions on presenteeism to employers: A review of the literature. Pharmacoeconomics 27:365-378, 2009.
16. Schoenwetter WF, Dupclay L Jr, Appajosyula S, et al. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin 20:305-317, 2004.
17. Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin 22:1203-1210, 2006.
18. Sheikh A, Hurwitz B, Nurmatov U, and Van Schayck CP. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev (7): CD001563, 2010.
19. Gotzsche PC, and Johansen HK. House dust mite control measures for asthma. Cochrane Database Syst Rev (2): CD001187, 2008.
20. Wood RA, Chapman MD, Adkinson NF Jr, and Eggleston PA. The effect of cat removal on allergen content in household-dust samples. J Allergy Clin Immunol 83:730-734, 1989.
21. Arbes SJ Jr, Cohn RD, Yin M, et al. Dog allergen (Can f 1) and cat allergen (Fel d 1) in US homes: Results from the National Survey of Lead and Allergens in Housing. J Allergy Clin Immunol 114:111-117, 2004.
22. Arbes SJ Jr, Sever M, Archer J, et al. Abatement of cockroach allergen (Bla g 1) in low-income, urban housing: A randomized controlled trial. J Allergy Clin Immunol 112:339-345, 2003.
23. Morgan WJ, Crain EF, Gruchalla RS, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 351:1068-1080, 2004.
24. Phipatanakul W, Matsui E, Portnoy J, et al. Environmental assessment and exposure reduction of rodents: A practice parameter. Ann Allergy Asthma Immunol 109:375-387, 2012.
25. Portnoy J, Kennedy K, Sublett J, et al. Environmental assessment and exposure control: A practice parameter-furry animals. Ann Allergy Asthma Immunol 108:223. e1-15, 2012.
26. Portnoy J, Miller JD, Williams PB, et al. Environmental assessment and exposure control of dust mites: A practice parameter. Ann Allergy Asthma Immunol 111:465-507, 2013.
27. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 354:1985-1997, 2006.
28. Strunk RC, Sternberg AL, Szefler SJ, et al. Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. J Pediatr 154:682-687, 2009.
29. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 129:717-725. e5, 2012.
30. Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study. J Allergy Clin Immunol 126:969-975, 2010.
31. Akdis M, and Akdis CA. Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 133:621-631, 2014.
32. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 99:450-453, 1997.
33. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma:10-year follow-up on the PAT study. Allergy 62:943-948, 2007.
34. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 114:851-857, 2004.
35. Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: Practical implications for the clinician. J Allergy Clin Immunol Pract 1:228-241, 2013.
36. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 131:1288-1296. e3, 2013.
37. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 7:6, 2014.
38. Radulovic S, Wilson D, Calderon M, and Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 66:740-752, 2011.
39. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev (1): CD001936, 2007.
40. Howarth P, Malling HJ, Molimard M, and Devillier P. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. Allergy 67:321-327, 2012.
41. Varney VA, Gaga M, Frew AJ, et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 302:265-269, 1991.
42. Noon L. Prophylactic inoculation against hay fever. Lancet 1:1572-1573, 1911.
43. Cox L. Sublingual immunotherapy for aeroallergens: Status in the United States. Allergy Asthma Proc 35:34-42, 2014.
44. Cox L, and Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 103:451-459; quiz 459-461, 495, 2009.
45. Sikora JM, Tankersley MS, and ACAAI Immunotherapy and Diagnostics Committee. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: A follow-up survey. Ann Allergy Asthma Immunol 110:194-7. e4, 2013.
46. Tucker MH, and Tankersley MS. Perception and practice of sublingual immunotherapy among practicing allergists. Ann Allergy Asthma Immunol 101:419-425, 2008.
47. GRASTEK (Timothy Grass Pollen Allergen Extract). Available online at http://www.fda.gov/downloads/BiologicsBloodVaccines/Allergenics/UCM393184.pdf; accessed December 14, 2014.
48. ORALAIR (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract). Available online at http://www.fda.gov/downloads/BiologicsBloodVaccines/Allergenics/UCM391580.pdf; accessed April 26, 2015.
49. RAGWITEKTM (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use Prescribing Information. Available online at http://www.merck.com/product/usa/pi-circulars/r/ragwitek/ragwitek-pi.pdf; accessed December 26, 2014.
50. Greer Standardized Mite Extracts Prescribing Information. Available online at http://www.greerlabs.com/files/DFU/L-505-Mites-w.pdf; accessed May 24, 2015.
51. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 127:S1-S55, 2011.
52. Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: A practice parameter update 2012. J Allergy Clin Immunol 131:295-299. e1-27, 2013.
53. Bae JM, Choi YY, Park CO, et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 132:110-117, 2013.
54. Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol 135:1275-1282. e6, 2015.
55. Burks AW, Jones SM, Wood RA, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med 367:233-243, 2012.
56. Burks AW, Wood RA, Jones SM, et al. Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. J Allergy Clin Immunol 135:1240-1248. e1-3, 2015.
57. Pajno GB, Cox L, Caminiti L, et al. Oral immunotherapy for treatment of immunoglobulin e-mediated food allergy: The transition to clinical practice. Pediatr Allergy Immunol Pulmonol 27:42-50, 2014.
58. Wood RA, and Sampson HA. Oral immunotherapy for the treatment of peanut allergy: Is it ready for prime time? J Allergy Clin Immunol Pract 2:97-98, 2014.
59. Coop CA, and Tankersley MS. Patient perceptions regarding local reactions from allergen immunotherapy injections. Ann Allergy Asthma Immunol 101:96-100, 2008.
60. Cox LS, Larenas-Linnemann D, Nolte H, et al. Sublingual immunotherapy: A comprehensive review. J Allergy Clin Immunol 117:1021-1035, 2006.
61. Cox L, Larenas-Linnemann D, Lockey RF, and Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 125:569-574, 574.e1-574.e7, 2010.
62. Epstein TG, Liss GM, Murphy-Berendts K, and Bernstein DI. AAAAI/ACAAI Surveillance study of subcutaneous immunotherapy, years 2008-2012: An update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract 2:161-167. e3, 2014.
63. Bernstein DI, Epstein T, Murphy-Berendts K, and Liss GM. Surveillance of systemic reactions to subcutaneous immunotherapy injections: Year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol 104:530-535, 2010.
64. Amin HS, Liss GM, and Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 117:169-175, 2006.
65. Cox L, Aaronson D, Casale TB, et al. Allergy immunotherapy safety: Location matters! J Allergy Clin Immunol Pract 1:455-457, 2013.
66. Calderon MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: Mode of action and its relationship with the safety profile. Allergy 67:302-11, 2012.
67. Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy 61(suppl. 82):1-20, 2006.
68. Cox LS, Hankin C, and Lockey R. Allergy immunotherapy adherence and delivery route: Location does not matter. J Allergy Clin Immunol Pract 2:156-160, 2014.
69. Bender BG, and Oppenheimer J. The special challenge of nonadherence with sublingual immunotherapy. J Allergy Clin Immunol Pract 2:152-155, 2014.
70. Incorvaia C, Rapetti A, Scurati S, et al. Importance of patient's education in favouring compliance with sublingual immunotherapy. Allergy 65:1341-1342, 2010.
71. Vita D, Caminiti L, Ruggeri P, and Pajno GB. Sublingual immunotherapy: Adherence based on timing and monitoring control visits. Allergy 65:668-669, 2010.
72. Creticos PS, Esch RE, Couroux P, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol 133:751-758, 2014.
73. Matricardi PM, Kuna P, Panetta V, et al. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: A comparison based on meta-analyses. J Allergy Clin Immunol 128:791-799. e6, 2011.
74. Cox L. Allergy immunotherapy in reducing healthcare cost. Curr Opin Otolaryngol Head Neck Surg 23:247-254, 2015.
75. Ariano R, Berto P, Tracci D, et al. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc 27:159-163, 2006.
76. Meadows A, Kaambwa B, Novielli N, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess 17: vi, xi-xiv, 1-322, 2013.
77. Hankin CS, and Cox L. Allergy immunotherapy: What is the evidence for cost saving? Curr Opin Allergy Clin Immunol 14:363-370, 2014.
78. Hankin CS, Cox L, Bronstone A, and Wang Z. Allergy immunotherapy: Reduced health care costs in adults and children with allergic rhinitis. J Allergy Clin Immunol 131:1084-1091, 2013.
79. Hankin CS, Cox L, Lang D, et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: A large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol 104:79-85, 2010.
80. Hankin CS, Cox L, Lang D, et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: Patterns of care, resource use, and costs. J Allergy Clin Immunol 121:227-232, 2008.
81. Nelson HS. Multiallergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol 123:763-769, 2009.
82. Calderon MA, Cox L, Casale TB, et al. Multiple-allergen and singleallergen immunotherapy strategies in polysensitized patients: Looking at the published evidence. J Allergy Clin Immunol 129:929-934, 2012.
83. Calderon MA, and Cox LS. Monoallergen sublingual immunotherapy versus multiallergen subcutaneous immunotherapy for allergic respiratory diseases: A debate during the AAAAI 2013 Annual Meeting in San Antonio, Texas. J Allergy Clin Immunol Pract 2:136-143, 2014.
84. Copenhaver CC, Parker A, and Patch S. Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice. Ann Allergy Asthma Immunol 107:441-447, 2011.
85. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341:468-475, 1999.
86. Cox L, and Cohn JR. Duration of allergen immunotherapy in respiratory allergy: When is enough, enough? Ann Allergy Asthma Immunol 98:416-426, 2007.